All lobbying filings

THE MCMANUS GROUP

Lobbying for VIVEX BIOLOGICS · Biologics Company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Florida · House · Senate · $50,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 1

S 2561
Skin Substitute Access and Payment Reform Act of 2025

Lobbying activity 2

Health Issues

Education on Human Cellular Tissue Products (HCTPs).

Medicare/Medicaid

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Physician Fee Schedule Proposed Rule (CMS-1832-P). Skin Substitute Access and Payment Reform Act of 2025 (S. 2561)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.